Jing Han Ng1, Angela An Qi See2,3, Zheyu Xu4, Nicolas Kon Kam King5,6,7. 1. Yong Loo Lin School of Medicine, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore, 119077, Singapore. 2. Department of Neurosurgery, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore. 3. Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore. 4. Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore. 5. Department of Neurosurgery, Singapore General Hospital, Outram Road, Singapore, 169608, Singapore. nicolaskon@gmail.com. 6. Department of Neurosurgery, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore. nicolaskon@gmail.com. 7. Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore. nicolaskon@gmail.com.
Abstract
INTRODUCTION: Deep brain stimulation of the subthalamic nucleus (STN DBS) has been shown to reduce antiparkinsonian medication in Parkinson's disease. We aimed to investigate the changes in long-term medication profile with STN DBS. METHODS: Antiparkinsonian medication data for 56 patients were collected from as early as 3 years before STN DBS up to 10 years after. Cost spending on medication changes was analyzed. Mean levodopa equivalent daily dose (LEDD) was projected 10 years into the future based on preoperative data to create a comparator group wherein the patients did not undergo STN DBS. Use of neuroleptics and antidepressants was also recorded. RESULTS: LEDD requirement was significantly reduced by a mean of 31 ± 2% over 10 years after DBS, from 1049 ± 381 mg at pre-DBS baseline, to 713 ± 392 mg at 1 year post-DBS, and 712 ± 385 mg at 10 years post-DBS. This was associated with a mean reduction of 35 ± 3% in medicine cost. Modeled LEDD requirements for not having STN DBS were in the range of 1489 mg to 2721 mg at 10 years post-DBS (109-282% higher than the observed mean LEDD in DBS cohort). The proportion of patients increased from 5% before STN DBS to 14% at 10 year post-DBS for neuroleptics, and 11-23% for antidepressants. CONCLUSION: STN DBS led to LEDD reduction and antiparkinsonian medication cost savings in our South-East Asian cohort. Medication reduction with STN DBS in our cohort over the 10-year period was comparable to those reported in Western populations.
INTRODUCTION: Deep brain stimulation of the subthalamic nucleus (STN DBS) has been shown to reduce antiparkinsonian medication in Parkinson's disease. We aimed to investigate the changes in long-term medication profile with STN DBS. METHODS: Antiparkinsonian medication data for 56 patients were collected from as early as 3 years before STN DBS up to 10 years after. Cost spending on medication changes was analyzed. Mean levodopa equivalent daily dose (LEDD) was projected 10 years into the future based on preoperative data to create a comparator group wherein the patients did not undergo STN DBS. Use of neuroleptics and antidepressants was also recorded. RESULTS: LEDD requirement was significantly reduced by a mean of 31 ± 2% over 10 years after DBS, from 1049 ± 381 mg at pre-DBS baseline, to 713 ± 392 mg at 1 year post-DBS, and 712 ± 385 mg at 10 years post-DBS. This was associated with a mean reduction of 35 ± 3% in medicine cost. Modeled LEDD requirements for not having STN DBS were in the range of 1489 mg to 2721 mg at 10 years post-DBS (109-282% higher than the observed mean LEDD in DBS cohort). The proportion of patients increased from 5% before STN DBS to 14% at 10 year post-DBS for neuroleptics, and 11-23% for antidepressants. CONCLUSION:STN DBS led to LEDD reduction and antiparkinsonian medication cost savings in our South-East Asian cohort. Medication reduction with STN DBS in our cohort over the 10-year period was comparable to those reported in Western populations.
Entities:
Keywords:
Antiparkinsonian medication; Asian; Cost analysis; Deep brain stimulation; Long term; Parkinson’s disease; Subthalamic nucleus
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: Galit Kleiner-Fisman; Jan Herzog; David N Fisman; Filippo Tamma; Kelly E Lyons; Rajesh Pahwa; Anthony E Lang; Günther Deuschl Journal: Mov Disord Date: 2006-06 Impact factor: 10.338
Authors: Frances M Weaver; Kevin T Stroupe; Lishan Cao; Robert G Holloway; Barbara G Vickrey; Tanya Simuni; Ann Hendricks; Dolores Ippolito Journal: Mov Disord Date: 2012-09-13 Impact factor: 10.338
Authors: Alfonso Fasano; Luigi M Romito; Antonio Daniele; Carla Piano; Massimiliano Zinno; Anna Rita Bentivoglio; Alberto Albanese Journal: Brain Date: 2010-09 Impact factor: 13.501
Authors: W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245